THAR
NASDAQ
Tharimmune, Inc. - Common Stock
Healthcare
· Biotechnology
$3.26
▲ +$0.02
(+0.62%)
Vol 386K
3
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$110.4M
ROE
-298.0%
D/E
2.62
Beta
1.50
52W
$1–$9
Price Chart
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -605.5% | -605.5% | -605.5% | -605.5% | -605.5% | -298.0% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 67.98 | 67.98 | 67.98 | 67.98 | 67.98 | 2.62 |
| Current Ratio | 1.17 | 1.17 | 1.17 | 1.17 | 1.17 | 4.98 |
Key Ratios
ROA (TTM)
-264.4%
P/B
3.0
EPS (TTM)
$-4.11
52W High
$9.08
52W Low
$0.95
$0.95
52-Week Range
$9.08
How does THAR compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
THAR valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
—
▼
0%
below
peers
(12.9)
vs Peers
vs Industry
Overvalued
P/B ratio
3.0
▲
22%
above
peers
(2.5)
vs Peers
vs Industry
Pricier
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
THAR profitability vs Biotechnology peers
ROE
-298.0%
▼
343%
below
peers
(-67.3%)
vs Peers
vs Industry
Weak
Net margin
—
▼
0%
below
peers
(-286.8%)
vs Peers
vs Industry
Top tier
Gross margin
—
▼
0%
below
peers
(78.6%)
vs Peers
vs Industry
In line
ROA
-264.4%
▼
466%
below
peers
(-46.7%)
vs Peers
vs Industry
Weak
THAR financial health vs Biotechnology peers
D/E ratio
2.6
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
In line
Current ratio
5.0
▲
12%
above
peers
(4.4)
vs Peers
vs Industry
In line
Beta
1.5
▲
54%
above
peers
(1.0)
vs Peers
vs Industry
More volatile
THAR fundamentals radar
THAR
Peer median
Industry
THAR profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
THAR vs peers: key metrics
Latest News
No related news yet